Degron Therapeutics raises $40M in Series A extension, total $95M, as Cabaletta releases early CAR‑T data

Degron Therapeutics, a US‑China biotech focused on molecular‑glue degrader technology, announced an additional $40 million in Series A extension funding, bringing its total capital raised to $95 million.

The new capital will be used to advance the company’s degrader platform and move pipeline candidates further toward clinical development.

In the same news briefing, Cabaletta Bio shared early endpoint data from its CAR‑T cell therapy program, providing the first readout of its latest trial.

While the data were presented, detailed efficacy and safety results were not included in the brief, leaving further evaluation pending.